treatment of heart failure

• Healthcare
• Pharma & Biotech
• Switzerland

Novartis: FDA grants priority review designation to investigational medicine for the treatment of heart failure

Decision could speed access to LCZ696 for HFrEF patients in the US, reducing total review time from 12 to 8…